Wholly Owned Pipeline

PureTech's Wholly Owned Programs are designed to harness immunological and lymphatic system mechanisms for the treatment of lung dysfunction, oncology, lymphatic, neurological and neuropsychological disorders.

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Initiation of Phase 2a POC study in H2 2020

1

Lymphatic flow disorders, incl. lymphedema

~1M

Product candidate for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., IPF, uILDs and Long COVID respiratory complications and related sequelae) and lymphedema.

LYT-100
Deupirfenidone
Long COVID1 respiratory complications & related sequelae
Initiation of Phase 2 study in H2 2020

1

Long COVID respiratory complications & related sequelae

Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders, such as IPF

1

Other fibrotic & inflammatory disorders, such as IPF

~130K (IPF or uILD)


Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND & initiation of Phase 1 study in 2020

Preclinical

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


LYT-200 is a fully human IgG4 mAb that is designed to block galectin-9, which we are developing for the treatment of solid tumors, including PDAC, CRC and CCA, that do not respond to approved checkpoint inhibitors and have poor survival rates.

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


LYT-210 is a fully human IgG1 mAb directed against the δ1 chain of T cells bearing γδT cell receptors (TCRs) we are designing for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

LYT-300
Oral Allopregnanolone
Neurological indications

Preclinical

Neurological indications

LYT-300 is an oral form of FDA-approved allopregnanolone, which is currently marketed in the U.S. as ZulressoTM and administrated as a 60-hour intravenous infusion. An oral form of allopregnanolone and other neurosteroids would enable the development of these natural molecules for treating a range of neurological and neuropsychological conditions.
Phase completedPhase in progress

 

1. Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection. 

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with several pharma companies or their investment arms